AVALO THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AVALO THERAPEUTICS, INC. (AVTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.31M, a 95.22% increase year-over-year.
- AVALO THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.58M, a 10.31% increase year-over-year.
- AVALO THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $4.51M, a 55.23% increase year-over-year.
- AVALO THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.15M, a 70.62% increase year-over-year.
- AVALO THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $13.62M, a 132.76% increase from fiscal 2024.
- AVALO THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.85M, a 68.31% increase from fiscal 2023.
- AVALO THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.48M, a 53.97% decline from fiscal 2022.
- AVALO THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $7.55M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.31M 10-Q · filed 2026-08-06 | $8.88M 10-Q · filed 2026-08-06 | $13.39M derived: sum of 3 quarters · filed 2026-08-06 | $16.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.58M 10-Q · filed 2026-05-13 | $8.08M derived: sum of 2 quarters · filed 2026-05-13 | $11.24M derived: sum of 3 quarters · filed 2026-05-13 | $13.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $7.66M derived: sum of 2 quarters · filed 2026-03-23 | $10.38M derived: sum of 3 quarters · filed 2026-08-06 | $13.62M 10-K · filed 2026-03-23 |
| 2025-09-30 | $3.15M 10-Q · filed 2025-11-06 | $5.87M derived: sum of 2 quarters · filed 2026-08-06 | $9.11M 10-Q · filed 2025-11-06 | $12.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.72M 10-Q · filed 2026-08-06 | $5.96M 10-Q · filed 2026-08-06 | $8.86M derived: sum of 3 quarters · filed 2026-08-06 | $10.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.24M 10-Q · filed 2026-05-13 | $6.14M derived: sum of 2 quarters · filed 2026-05-13 | $7.99M derived: sum of 3 quarters · filed 2026-05-13 | $8.46M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $4.75M derived: sum of 2 quarters · filed 2026-03-23 | $5.22M derived: sum of 3 quarters · filed 2026-03-23 | $5.85M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.85M 10-Q · filed 2025-11-06 | $2.32M derived: sum of 2 quarters · filed 2025-11-06 | $2.95M 10-Q · filed 2025-11-06 | $3.72M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $471.00K 10-Q · filed 2025-08-07 | $1.10M 10-Q · filed 2025-08-07 | $1.88M derived: sum of 3 quarters · filed 2025-08-07 | $2.83M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $629.00K 10-Q · filed 2025-05-12 | $1.41M derived: sum of 2 quarters · filed 2025-05-12 | $2.36M derived: sum of 3 quarters · filed 2025-05-12 | $3.25M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $776.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.73M derived: sum of 2 quarters · filed 2025-03-20 | $2.62M derived: sum of 3 quarters · filed 2025-03-20 | $3.48M 10-K · filed 2025-03-20 |
| 2023-09-30 | $953.00K 10-Q · filed 2024-11-07 | $1.85M derived: sum of 2 quarters · filed 2024-11-07 | $2.70M 10-Q · filed 2024-11-07 | $3.54M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $893.00K 10-Q · filed 2024-08-12 | $1.75M 10-Q · filed 2024-08-12 | $2.59M derived: sum of 3 quarters · filed 2024-08-12 | $3.32M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $855.00K 10-Q/A · filed 2024-07-11 | $1.70M derived: sum of 2 quarters · filed 2024-07-11 | $2.43M derived: sum of 3 quarters · filed 2024-07-11 | |
| 2022-12-31 | $843.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.57M derived: sum of 2 quarters · filed 2024-03-29 | $7.55M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $731.00K 10-Q · filed 2023-11-09 | $6.71M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |